Rohto Pharmaceutical Co.,Ltd.

TSE:4527 Stock Report

Market Cap: JP¥658.4b

Rohto PharmaceuticalLtd Management

Management criteria checks 3/4

Rohto PharmaceuticalLtd's CEO is Yamada Kunio, appointed in Jun 2009, has a tenure of 14.83 years. total yearly compensation is ¥205.00M, comprised of 89.3% salary and 10.7% bonuses, including company stock and options. directly owns 1.74% of the company’s shares, worth ¥11.48B. The average tenure of the management team and the board of directors is 2.1 years and 4.8 years respectively.

Key information

Yamada Kunio

Chief executive officer

JP¥205.0m

Total compensation

CEO salary percentage89.3%
CEO tenure14.8yrs
CEO ownership1.7%
Management average tenure2.1yrs
Board average tenure4.8yrs

Recent management updates

Recent updates

These 4 Measures Indicate That Rohto PharmaceuticalLtd (TSE:4527) Is Using Debt Safely

Apr 03
These 4 Measures Indicate That Rohto PharmaceuticalLtd (TSE:4527) Is Using Debt Safely

Here's Why We Think Rohto PharmaceuticalLtd (TSE:4527) Is Well Worth Watching

Mar 21
Here's Why We Think Rohto PharmaceuticalLtd (TSE:4527) Is Well Worth Watching

Rohto PharmaceuticalLtd (TSE:4527) Is Paying Out A Larger Dividend Than Last Year

Mar 07
Rohto PharmaceuticalLtd (TSE:4527) Is Paying Out A Larger Dividend Than Last Year

Estimating The Intrinsic Value Of Rohto Pharmaceutical Co.,Ltd. (TSE:4527)

Feb 26
Estimating The Intrinsic Value Of Rohto Pharmaceutical Co.,Ltd. (TSE:4527)

CEO Compensation Analysis

How has Yamada Kunio's remuneration changed compared to Rohto PharmaceuticalLtd's earnings?
DateTotal CompensationSalaryCompany Earnings
Dec 31 2023n/an/a

JP¥31b

Sep 30 2023n/an/a

JP¥30b

Jun 30 2023n/an/a

JP¥28b

Mar 31 2023JP¥205mJP¥183m

JP¥26b

Dec 31 2022n/an/a

JP¥26b

Sep 30 2022n/an/a

JP¥23b

Jun 30 2022n/an/a

JP¥23b

Mar 31 2022JP¥196mJP¥178m

JP¥21b

Dec 31 2021n/an/a

JP¥23b

Sep 30 2021n/an/a

JP¥21b

Jun 30 2021n/an/a

JP¥20b

Mar 31 2021JP¥185mJP¥176m

JP¥17b

Dec 31 2020n/an/a

JP¥14b

Sep 30 2020n/an/a

JP¥14b

Jun 30 2020n/an/a

JP¥15b

Mar 31 2020JP¥192mJP¥179m

JP¥15b

Dec 31 2019n/an/a

JP¥11b

Sep 30 2019n/an/a

JP¥10b

Jun 30 2019n/an/a

JP¥9b

Mar 31 2019JP¥181mJP¥173m

JP¥10b

Compensation vs Market: Yamada's total compensation ($USD1.33M) is above average for companies of similar size in the JP market ($USD898.91K).

Compensation vs Earnings: Yamada's compensation has been consistent with company performance over the past year.

CEO

Yamada Kunio (67 yo)

14.8yrs

Tenure

JP¥205,000,000

Compensation

Mr. Yamada Kunio had been the President at Rohto Pharmaceutical Co. Ltd. since June 9, 2009 until 2019. Mr. Kunio has been the Chairman of the Board of Directors and Representative Director at Rohto Pharma...

Leadership Team

NamePositionTenureCompensationOwnership
Yamada Kunio
Chairman of the Board & CEO14.8yrsJP¥205.00m1.74%
¥ 11.5b
Masashi Sugimoto
President & Representative Director4.8yrsno data0.0066%
¥ 43.3m
Saito Masaya
VP, CFO & Director2.1yrsno data0.020%
¥ 132.7m
Shinichi Kunisaki
EVP, CTO & Director2.1yrsno data0.017%
¥ 112.5m
Yoshie Ohkouchi
Chief Communication Officer & Directorless than a yearno datano data
Hideto Kamimura
Senior Executive Officer and General Manager of Marketing Division no datano data0.0048%
¥ 31.7m
Yasunori Kawasaki
CHRO & Directorless than a yearno datano data
Hidetoshi Segi
MD, Chief Strategy Officer & Director2.1yrsno data0.0035%
¥ 23.1m

2.1yrs

Average Tenure

62yo

Average Age

Experienced Management: 4527's management team is considered experienced (2.1 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
Yamada Kunio
Chairman of the Board & CEO24.8yrsJP¥205.00m1.74%
¥ 11.5b
Masashi Sugimoto
President & Representative Director4.8yrsno data0.0066%
¥ 43.3m
Saito Masaya
VP, CFO & Director12.8yrsno data0.020%
¥ 132.7m
Shinichi Kunisaki
EVP, CTO & Director13.8yrsno data0.017%
¥ 112.5m
Yoshie Ohkouchi
Chief Communication Officer & Directorless than a yearno datano data
Yasunori Kawasaki
CHRO & Directorless than a yearno datano data
Hidetoshi Segi
MD, Chief Strategy Officer & Director5.8yrsno data0.0035%
¥ 23.1m
Kimura Masanori
Standing Corporate Auditor7.8yrsno data0.027%
¥ 176.1m
Akie Iriyama
Independent Outside Director4.8yrsno datano data
Haruka Mera
Independent Outside Director3.8yrsno datano data
Tatsuo Uemura
Independent Outside Director1.8yrsno datano data
Eriko Hayashi
Independent Outside director1.8yrsno datano data

4.8yrs

Average Tenure

61.5yo

Average Age

Experienced Board: 4527's board of directors are considered experienced (4.8 years average tenure).

Simply Wall St™
Simply Wall Street Pty Ltd
Level 7, 320 Pitt Street, Sydney
Download on the App StoreGet it on Google Play
Popular Markets
USAUUKINCAZA
About UsCareersPlansLogin
Help CenterLatest CoveragePodcastsAffiliate ProgramBusiness & Enterprise
Financial Services GuideTerms and ConditionsPrivacy PolicyLogos provided by Clearbit
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.